Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins
EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.